Common Contracts

3 similar Collaborative Development Agreement contracts by Audentes Therapeutics, Inc.

EX-10.12 9 d892618dex1012.htm COLLABORATIVE DEVELOPMENT AGREEMENT (GENETHON) * Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant...
Collaborative Development Agreement • May 5th, 2020 • England and Wales

This COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).

AutoNDA by SimpleDocs
COLLABORATIVE DEVELOPMENT AGREEMENT No. 013135-1MTUB-00
Collaborative Development Agreement • January 4th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales

This COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).

COLLABORATIVE DEVELOPMENT AGREEMENT No. 013135-1MTUB-00
Collaborative Development Agreement • December 18th, 2015 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales

This COLLABORATIVE DEVELOPMENT AGREEMENT (the “Agreement”), effective as of January 24, 2014 (the “Effective Date”), is made by and between Audentes Therapeutics, Inc., a Delaware corporation, having a place of business at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA (“Audentes”) and Genethon, a French not-for-profit organization organised under the French law of July 1, 1901, having a principal place of business at 1bis rue de l’Internationale, 91002 EVRY Cedex, France (“Genethon”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!